UBS Group’s Plus Therapeutics PSTV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.3K | Sell |
3,514
-31,520
| -90% | -$239K | ﹤0.01% | 8176 |
|
|
2025
Q4 | $448K | Buy |
35,034
+10,079
| +40% | +$152K | ﹤0.01% | 6158 |
|
|
2025
Q3 | $427K | Buy |
24,955
+21,449
| +612% | +$263K | ﹤0.01% | 6210 |
|
|
2025
Q2 | $30.5K | Buy |
3,506
+2,169
| +162% | +$28.4K | ﹤0.01% | 8146 |
|
|
2025
Q1 | $31.8K | Buy |
+1,337
| New | +$37.4K | ﹤0.01% | 7902 |
|
|
2024
Q3 | – | Sell |
-128
| Closed | -$4.7K | – | 9947 |
|
|
2024
Q2 | $4.7K | Buy |
+128
| New | +$6.28K | ﹤0.01% | 8059 |
|
|
2024
Q1 | – | Sell |
-356
| Closed | -$15.6K | – | 9876 |
|
|
2023
Q4 | $15.6K | Buy |
356
+150
| +73% | +$6.01K | ﹤0.01% | 7250 |
|
|
2023
Q3 | $6.9K | Buy |
+206
| New | +$11.1K | ﹤0.01% | 7263 |
|
|
2023
Q2 | – | Hold |
0
| – | -$4 | – | 9478 |
|
|
2023
Q1 | – | Sell |
-51
| Closed | -$6.86K | – | 9500 |
|
|
2022
Q4 | $6.08K | Buy |
51
+8
| +19% | +$1.27K | ﹤0.01% | 9082 |
|
|
2022
Q3 | $7K | Buy |
43
+6
| +16% | +$1.34K | ﹤0.01% | 8895 |
|
|
2022
Q2 | $7K | Buy |
+37
| New | +$9.24K | ﹤0.01% | 8519 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 10764 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 10596 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 9966 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 9722 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 9367 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 8666 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 8321 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 8336 |
|
|
2019
Q3 | – | Sell |
-1
| Closed | -$3.61K | – | 8201 |
|
|
2019
Q2 | $4K | Buy |
+1
| New | +$5.16K | ﹤0.01% | 7460 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 8062 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 8235 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 8199 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 8185 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 7012 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 7617 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6531 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 7511 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6906 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 7638 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 7416 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 7050 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6932 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6214 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6748 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 7880 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 7822 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 8234 |
|
Other funds holding PSTV
VCM
VFT
TSS
XT
UBS Group's PSTV Position: Q1 2026 in Review
UBS Group reduced its Plus Therapeutics (PSTV) stake by 90% in Q1 2026, selling an estimated $239K and leaving 3,514 shares worth $14.3K. The position accounts for ﹤0.01% of the portfolio, ranked #8176.
UBS Group first reported a position in PSTV in Q2 2019 and has held it in 12 quarters since. The position peaked at $448K in Q4 2025. 23 funds tracked by Wall St. Rank hold PSTV as of Q1 2026.
- UBS Group held 3,514 shares of Plus Therapeutics worth $14.3K as of Q1 2026.
- UBS Group sold 31,520 Plus Therapeutics shares in Q1 2026, an estimated $239K.
- Plus Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8176 holding.
- UBS Group first reported a position in Plus Therapeutics in Q2 2019 and has held it in 12 quarters since.
- UBS Group's Plus Therapeutics position peaked at $448K in Q4 2025.
- 23 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.